Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancerPier‐Luc Clermont, Cheryl D. Helgason, Yuzhuo Wang et al.|Clinical Epigenetics|2016Cited by 78
CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13Jean C. Tien, Arul M. Chinnaiyan, Jie Luo et al.|Cell Reports Medicine|2024Cited by 28
Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancerTongchen He, Arul M. Chinnaiyan, Caleb Cheng et al.|Proceedings of the National Academy of Sciences|2024Cited by 22
Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory responseYuanyuan Qiao, Arul M. Chinnaiyan, Jesse W. Wotring et al.|Proceedings of the National Academy of Sciences|2023Cited by 8
Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancerTongchen He, Arul M. Chinnaiyan, Caleb Cheng et al.|bioRxiv (Cold Spring Harbor Laboratory)|2024Cited by 4